Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
National Institute for Health and Care Excellence (NICE)
Record ID 32018013613
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1018
Year Published:
2024
URL for published report:
https://www.nice.org.uk/guidance/ta1018
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Splenomegaly
- Primary Myelofibrosis
- Janus Kinase 2
- Janus Kinase Inhibitors
- Protein Kinase Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.